Company: RGBP
Filing Date: 2025-10-03
Form Type: 8-K
Source: 0001493152-25-016767
Chunk: 1

Company: Regen BioPharma Inc
Filing Date: 2025-10-03
Form: 8-K
Item: Item 1.01
Chunk 1
---

Koos Compensation Shares shall vest upon successful completion of planned Phase I Clinical Trial of HemaXellerate, such Clinical Trial
having been conducted with the assistance of the Consultant pursuant to the terms and conditions of this Agreement.

The
foregoing description of the abovementioned Koos Agreement is not complete and is qualified in its entirety by reference to the text
of the abovementioned Koos Agreement which is attached to this Current Report on Form 8-K as Exhibit 10.2 and incorporated in this Item
1.01 by reference.

HemaXellarate, a stem cell derived therapy being developed by the Company, is a cellular composition of autologous stromal vascular fraction derived
from adipose tissue. The Company intends to initiate a Phase I clinical trial assessing HemaXellerate in patients with drug-refractory
aplastic anemia. The Phase I clinical trial is intended to determine safety and potential efficacy of intravenously administered autologous
stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia with the primary endpoints
of safety and feasibility and secondary endpoints of efficacy as determined by patients having complete response, partial response or
relapse.

3.02
Unregistered Sales of Equity Securities

On
October 2, 2025 the Company issued twenty million newly issued common shares of the Company to
Harry Lander pursuant to the Lander Agreement and subject to a vesting schedule.

On
October 2, 2025 the Company issued twenty million newly issued common shares of the Company to
David Koos pursuant to the Koos Agreement and subject to a vesting schedule.

All
of the abovementioned securities were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”).
No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission
or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in
connection with this Offer and Sale of shares.

As
a result of the issuance of the abovementioned securities as of October 3, 2025 Regen Biopharma, Inc. has 79,374,704 common shares outstanding.

Item
8.01. Other Events